Ibio Inc (IBIO)
$1.51
0.05 (3.42%)
IBIO Stock Quote Delayed 30 Minutes
Previous Close
-
Market Cap
24.07M
PE Ratio
-0.89
EPS
-1.7
Volume (Avg. Vol.)
6.77M
Day's Range
1.40 - 1.53
52-Week Range
0.11 - 7.45
Dividend & Yield
N/A (N/A)
IBIO Stock Predictions, Articles, and Ibio Inc News
It’s Time for iBio Speculators to Consider Something Else
One of the more intriguing high-risk, high-reward ideas in the Covid-19 space, IBIO stock had an opportunity to distinguish itself. But with the vaccine race heating up, the dangers outweigh the possibilities.
iBio Looks Well-Positioned to Succeed
iBio reports impressive Q1 results as biotech companies see a strong rally this year. Here’s the latest on IBIO stock.
Why iBio Presents a Dilemma to Shareholders
iBio’s first-quarter included steep losses and not much else. If IBIO stock is to rise to $2, investors need some good news to chew on.
Stay Away From iBio, Which Constantly Issues Shares to Survive
The latest in IBIO news: stay away from IBIO stock, which has over-issued shares to survive. The stock remains below the average issue price.
Up 600% Year-to-Date, Sell iBio Stock While It’s Still Flying High
The latest iBio news isn't good. It's taken too long for IBIO to develop a coronavirus vaccine and now the opportunity has disappeared.
Two Covid-19 Vaccine Candidates Hold Promise for iBio
iBio has a huge vertical farming facility and a couple of high-potential vaccine candidates, which should offer hope to IBIO stock holders.
iBio Remains a Biotech Sideline Play as Covid Rages
Investor interest a unique production system isn’t enough to make buying IBIO stock a worthwhile move at this time.
First to COVID-19 Vaccine or Not, iBio Is a Smart Investment
IBIO stock has been hit hard by its apparent failure to produce the first COVID-19 vaccine, but that’s a simplistic view of iBio’s prospects.
IBIO Stock Remains a Speculative Biopharma Play
Yes, I will continue to root for Ibio in its fight to make a huge leap with its Covid-19 efforts. But where my investment dollar is concerned, it'll be from the sidelines.
The Low-Hanging Fruit for Covid-19 Vaccines Is Gone for iBio
With the viable candidate pool for novel coronavirus vaccines shrinking, this angle is probably closed to IBIO stock. However, speculators still have a shot with the therapeutic approach.
IBIO Remains a Purely Speculative Bet
IBIO stock is a purely speculative bet compared to better options when it comes to investing in Covid-19 vaccine development.
Why iBio Is a Buy for Investors Thinking Past the Vaccine Race
An investment in IBIO stock is a bet on the company’s unique FastPharming system to create medications and therapies of all sorts.
IBio Stock Is Not Worth a Gamble at This Stage
IBIO stock is in a rough spot with minimal progress in its Covid-19 vaccine and its FastPharming technology.
A Dice-Roll on iBio Stock Is Much Less Appealing Now
Since hitting $1.70 on Aug. 21, IBIO stock has gone sideways. With little on the news front over the past seven weeks, it’s easy to see why.
At This Stage of the Vaccine Race, Is Now a Good Time to Buy iBio Stock?
Most bulls buying into IBIO stock the past few months are underwater. But that short-term pain may have finished.
Get Out of IBIO Stock Before It’s Too Late
Since peaking at $7.45 per share in July, iBio's stock price has fallen further from its 52-week high as hopes fade for the company to make a meaningful impact towards a cure for Covid-19. Today, IBIO stock is trading at just over $2 a share, about the same level it was at in early March of this year. Investors would be wise to sell this stock now before its price falls even more in coming weeks.
This Is Why I’d Still Avoid IBio for Now
With no real vaccine news to speak of, I’d avoid the IBIO stock for now. If they can get something going, it may be worth a look.
iBio Will Survive Coronavirus Vaccine Disappointment, But It’s not a ‘Buy’
Investors pondering how a company with a history of moving back-and-forth between micro- and small-cap territory could adequately compete against more well-heeled rivals were right to express those concerns and IBIO stock validated those worries.
iBio Is a Pure Spec Play That Remains a Day Trader’s Delight
IBIO stock will continue to ebb and flow as the pandemic rages on. Day traders should look out for positive clinical trial news as a buy-in signal.
Navellier Ratings
Powered by Portfolio GraderTotal Grade
A
